Opinion
Video
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.
- Were there any particularly exciting updates or data presented at ASH 2024 that could influence how BTK inhibitors are used in clinical practice for CLL and MCL?
